Also found in: Dictionary, Wikipedia.
Related to frovatriptan: Frovatriptan succinate


(froe-va-trip-tan) ,


(trade name)


Therapeutic: vascular headache suppressants
Pharmacologic: five ht1 agonists
Pregnancy Category: C


Acute treatment of migraine headache.


Acts as an agonist at specific 5-HT receptor sites in intracranial blood vessels and sensory trigeminal nerves.

Therapeutic effects

Cranial vessel vasoconstriction with associated decrease in release of neuropeptides and resultant decrease in migraine headache.


Absorption: 20–30% following oral administration.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver (P450 1A2 enzyme system); some metabolites eliminated in urine, <10% excreted unchanged.
Half-life: 26 hr.

Time/action profile (blood levels)

POunknown2–4 hrunknown


Contraindicated in: Hypersensitivity;History, symptoms or findings consistent with;Cerebrovascular syndromes including;Uncontrolled hypertension;Hemiplegic or basilar migraine;Peripheral vascular disease, including ischemic bowel disease;Should not be used within 24 hr of any other 5-HT agonist or ergot-type compounds (e.g. dihydroergotamine, ergotamine); Pediatric: Children <18 yr.
Use Cautiously in: Concurrent use of SSRIs or SNRIs (↑ risk of serotonin syndrome); Geriatric: May be more susceptible to adverse cardiovascular effects; Obstetric / Lactation: Safety not established.
Exercise Extreme Caution in: Cardiovascular risk factors (hypertension, hypercholesterolemia, cigarette smoking, obesity, diabetes, strong family history, menopausal women or men >40 yr); use only if cardiovascular status has been evaluated and determined to be safe and first dose is administered under supervision.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • drowsiness
  • fatigue


  • coronary artery vasospasm (life-threatening)
  • mi (life-threatening)
  • ventricular fibrillation (life-threatening)
  • ventricular tachycardia (life-threatening)
  • chest pain
  • myocardial ischemia


  • dry mouth
  • dyspepsia
  • nausea


  • flushing


  • skeletal pain


  • paresthesia


  • pain


Drug-Drug interaction

Hormonal contraceptives or propranolol may ↑ levels.↑ risk of serious vasospastic reactions with dihydroergotamine or ergotamine (concurrent use contraindicated).↑ risk of serotonin syndrome when used with fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, venlafaxine, or duloxetine.


Oral (Adults) 2.5 mg; if there has been initial relief, a second tablet may be taken after at least 2 hr (daily dose should not exceed 3 tablets and should not be used to treat more than 4 attacks/30 day period).


Tablets: 2.5 mg

Nursing implications

Nursing assessment

  • Assess pain location, intensity, duration, and associated symptoms (photophobia, phonophobia, nausea, vomiting) during migraine attack.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Oral: Tablets may be administered at any time after the headache starts.

Patient/Family Teaching

  • Inform patient that frovatriptan should be used only during a migraine attack. It is meant to be used to relieve migraine attack but not to prevent or reduce the number of attacks.
    • Instruct patient to administer frovatriptan as soon as symptoms appear, but it may be administered any time during an attack. If migraine symptoms return, a second dose may be used. Allow at least 2 hr between doses, and do not use more than 3 tablets in any 24-hr period.
    • If dose does not relieve headache, additional frovatriptan doses are not likely to be effective; notify health care professional.
    • Advise patient that lying down in a darkened room following frovatriptan administration may further help relieve headache.
    • Caution patient not to use frovatriptan if she is pregnant, suspects she is pregnant, plans to become pregnant, or is breast feeding. Adequate contraception should be used during therapy.
    • May cause dizziness or drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
    • Advise patient that overuse (use more than 10 days/month) may lead to exacerbation of headache (migraine-like daily headaches, or as a marked increase in frequency of migraine attacks). May require gradual withdrawal of frovatriptan and treatment of symptoms (transient worsening of headache).
    • Advise patient to notify health care professional prior to next dose of frovatriptan if pain or tightness in the chest occurs during use. If pain is severe or does not subside, notify health care professional immediately. If wheezing; heart throbbing; swelling of eyelids, face, or lips; skin rash; skin lumps; or hives occur, notify health care professional immediately and do not take more frovatriptan without approval of health care professional. If feelings of tingling, heat, flushing, heaviness, pressure, drowsiness, dizziness, tiredness, or sickness develop, discuss with health care professional at next visit.
    • Advise patient to avoid alcohol, which aggravates headaches, during frovatriptan use.

Evaluation/Desired Outcomes

  • Relief of migraine attack.


an antimigraine agent used for the acute treatment of migraine with or without aura.


A triptan-type selective serotonin receptor (5HT1B/1D receptor) agonist (SSRA) used in the acute management of migraine headaches and menstrual migraines.

Vasoconstriction of intracerebral arteries.

Adverse effects
Coronary artery vasospasm, transient myocardial ischaemia or infarction, ventricular tachycardia or fibrillation.


A long-acting SEROTONIN agonist drug (see TRIPTANS) used to treat MIGRAINE. A brand name is Migard.
References in periodicals archive ?
Savi's study plus two other published Italian randomized, double-blind crossover clinical trials of frovatriptan versus rizatriptan (Maxalt) (J.
The pooled subgroup analysis covered the 187 women with at least one episode of menstrual migraine treated with frovatriptan and one episode treated with one of the other triptans.
Recommended acute therapies for migraine attacks available in the United States NSAIDs * Aspirin * Ibuprofen * Naproxen sodium * Acetaminophen + aspirin + caffeine Opiates/barbiturate hypnotics * Intranasal butorphanol * Other opiates and butalbital-containing compounds may be considered for use as "rescue medications" Ergotamine and derivatives * DHE nasal spray * SC/IM/IV DHE * IV DHE and antiemetic Triptans * Almotriptan (tablets) * Eletriptan (tablets) * Frovatriptan (tablets) * Naratriptan (tablets) * Rizatriptan (tablets, orally disintegrating tablets) * Sumatriptan (tablets, nasal spray, subcutaneous injections, suppositories) * Zolmitriptan (tablets, nasal spray, orally disintegrating tablets) NSAIDs, nonsteroidal anti-inflammatory drugs; DHE, dihydroergotamine.
They said the combined group would maximise the potential of frovatriptan and progress existing discovery and development programmes with the greatest potential.
The class of triptans include sumatriptan (imitrex), rizatriptan (Maxalt), zolmitriptan (Zomig), naratriptan (Amerge), almotriptan (Axert), eletriptan (Relpax), and frovatriptan (Frova).
5 mg of frovatriptan either once or twice daily for 6 days at the time of menstruation had significantly fewer--and less severe--menstrual migraines, compared with women who took a placebo, reported Dr.
The Group has two approved products; Tuzistra(TM) XR targeting the US prescription cough cold market and, frovatriptan for the acute treatment of migraine.
Other poster presentations at the meeting detailed the efficacy of rizatriptan administered early in the course of menstrual migraines and the safety and tolerability of frovatriptan taken prophylactically each month in women with regular menstrual cycles.
Seven triptans indicated for the short-term treatment of migraine with or without aura are available: sumatriptan (Imitrex), almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), and zolmitriptan (Zomig).
A new drug, frovatriptan, may eliminate these issues for some.
Elan will realise a total consideration of approximately $55 million from Vernalis for rights to frovatriptan and related assets in North America, comprising the following additional payments: on December 31, 2004 and December 31, 2005, Elan will receive payments of $20 million and $25 million respectively; and no later than December 31, 2004, Elan will receive a payment for its Frova inventory, estimated at approximately $5 million.
If headaches recur, treat attacks earlier, increase the dose, switch triptans, particularly to naratriptan or frovatriptan, add an NSAID, or switch to dihydroergotamine mesylate, Dr.